drugset / Trial / NCT01869725

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

NCT01869725

NaSingle-groupOpen-labelDiagnostic

Summary

This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.

Timeline

Start
2013-04-01
Primary completion
2018-12-26
Completion
2018-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-DOTATOC Peptide Intravenous